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Abstract 
Background: Venous thromboembolism (VTE) is a major health care problem resulting in significant mortality, 
morbidity and increase in medical expenses. Patients with malignant diseases represent a high risk population for 
VTE. The American College of Chest Physicians (ACCP) proposed, since 1986, prophylaxis guidelines that are unequally 
respected in surgical practice.
Methods: DIONYS is a multinational, longitudinal and non-interventional registry including patients having under-
gone abdominal or pelvic surgery for cancer in Latin America, Africa and the Middle East. Patients were evaluated 
with regard to VTE prophylaxis, during three consecutive visits, for their adherence to ACCP 2008 guidelines. Data 
were collected on type and duration of VTE prophylaxis, adherence to guidelines, and compliance with prescriptions, 
complications and possible reasons for omission of prophylaxis.
Results: Between 2011 and June 2012, 921 adult patients were included and divided into abdominal (435), pelvic 
(390) and combined abdominal and pelvic surgery (96), 65.4 % being females. VTE prophylaxis was prescribed to 90 % 
of patients during hospitalization and to 28.3 % after hospital discharge. Prescriptions adhered to ACCP guidelines 
in 73.9 % of patients during hospitalization and 18.9 % after discharge. The reason of non-adherence was mainly the 
clinical judgment by the physician that the patient did not need a prophylaxis. The most commonly prescribed type 
of prophylaxis was pharmacological (low molecular weight heparin).
Conclusion: A wide gap exists between VTE prophylaxis in daily practice and the ACCP 2008 guidelines, in abdomi-
nal and pelvic cancer surgery. A better awareness of surgeons is probably the best guarantee for improvement of VTE 
prophylaxis in surgical wards.
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Background
Venous thromboembolism (VTE) is a disease entity that 
includes deep venous thrombosis (DVT) and pulmo-
nary embolism (PE). It is recognized to be a major global 
health care problem resulting in significant mortality, 
morbidity and increase in medical expenses, all over the 
world. Its yearly incidence is between 117 and 160 per 
100,000 in the general population, with a fatal PE rate of 
50 per 100,000, making it the third most common circu-
latory disorder in the West (Nordström et  al. 1992; Sil-
verstein et al. 1998; Lindblad et al. 1991; Heit et al. 2000). 
The prevention of this frequent disease is mandatory, but 
it seems insufficiently done in the surgical practice of the 
majority of countries.
Surgery is a major risk factor of VTE. In the absence of 
effective VTE prophylaxis, the rate of asymptomatic DVT 
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is reported to be 15–40 % in patients who undergo major 
abdominal or pelvic surgery resulting in 0.2–0.9 % rate of 
fatal PE event (Geerts et  al. 2008; Mismetti et  al. 2001). 
VTE is even more frequent in major orthopedic proce-
dures, occurring in up to 60 % of patients (Krska 2012).
Factors affecting the risk of VTE in surgery include 
the following: extension and duration of surgeries, can-
cer, previous VTE, prolonged hospitalization, delayed 
immobilization, obesity, increasing age, type of anesthe-
sia, postoperative infection, central venous catheter, pro-
thrombic chemotherapeutic agents, genetic factors and 
trauma (Clarke-Pearson et al. 2003; Jacobson et al. 2005; 
Tateo et  al. 2005; Martino et  al. 2006; Srinivasan and 
Watzak 2012; Tagalakis et al. 2013).
Cancer is a well- documented risk factor for VTE, ele-
vating its risk four to sevenfold when compared to the 
risk in cancer free patients (Heit et al. 2000). This asso-
ciation called Trousseau Syndrome is due to the key roles 
that angiogenesis and hemostasis play in the process of 
cancer genesis (Lecumberri et  al. 2005). Although the 
risk of postoperative DVT is highest within the 1st week 
or two after surgery, VTE complications including fatal 
PE may occur later, with a peak reported between days 14 
and 28 by some authors (Van Hemelrijck et al. 2013).
Extended VTE prophylaxis is a necessity to reduce the 
incidence of thrombotic complications in patients under-
going major surgeries. Scoring systems (Rogers, Caprini, 
IUAS) have been proposed (Caprini et  al. 1991; Rogers 
et al. 2012) to classify patients in low, moderate, high and 
highest risk levels. The American College of Chest Physi-
cians (ACCP) proposed guidelines based on these scor-
ing systems to help in assessment of risk factors and to 
implement an appropriate use of VTE prophylaxis. These 
international guidelines were first published in 1986 and 
subsequently updated until the ninth edition in 2012 
(Guyatt et al. 2012) by a panel of international experts. In 
case of abdominal or pelvic surgery for cancer, the guide-
lines recommend for high-VTE-risk patients who are not 
otherwise at high risk for major bleeding complications, 
a 4  week extended-duration pharmacologic prophylaxis 
with low molecular weight heparin (LMWH).
However, according to various sources, the VTE 
prophylaxis is far from optimal in current clinical prac-
tice. The adherence to international guidelines has been 
studied especially during the hospitalization period, and 
was shown to be low (Stratton et al. 2000; Kakkar et al. 
2003; Wolff 2003; Amin et al. 2008).
Most of the developing countries do not have a homog-
enous management of venous thrombo-prophylaxis in 
agreement with international guidelines (Zeitoun et  al. 
2009; Ouro-Bang’na Maman et  al. 2006; Arnaout et  al. 
2011; Bikdeli and Sharif-Kashani 2012; Mokhtari et  al. 
2011). For example, the ENDORSE study (Cohen et  al. 
2008) showed in 2006 that there were still low and heter-
ogeneous rates of appropriate prophylaxis, notably across 
Latin America, Africa and Middle East countries (from 
23 % in Venezuela to 78 % in Tunisia).
As the VTE risk continues after hospital discharge, further 
data are still needed on adherence and compliance of VTE 
prophylaxis with international guidelines concerning this 
post discharge period, regardless of the surgical procedure. 
Although such data have been obtained in major orthopedic 
interventions (Arcelus and Felicissimo 2013), they are still 
needed in abdominal and pelvic cancer surgery.
To answer these needs, a study has been performed 
within Latin America, Africa and Middle East countries: 
DIONYS (duration and adherence to International guide-
lines of venous thromboembolism prophylaxis in oncol-
ogy patients undergoing a major abdominal or pelvic 
Surgery) is an international longitudinal, prospective and 
observational registry comparing real life administration 
of VTE prophylaxis to international ACCP 2008 guide-
lines, both during hospitalization and after discharge, in 
patients having undergone a major abdominal or pelvic 
surgery for malignant tumor.
Methods
A longitudinal non-interventional registry have been 
designed for application in developing countries, namely 
Mexico and Venezuela (Latin America), Egypt (Africa), 
Saudi Arabia, Kuwait, United Arab Emirates (UAE), Syria 
and Lebanon (Middle East). The data from Kuwait and 
UAE were presented as a cluster because of limited sam-
ple size obtained in these 2 countries.
Study design
The DIONYS registry was designed early in 2010 and 
started to be applied in 2011. It was conducted in accord-
ance with the Declaration of Helsinki (1964), the Inter-
national Conference on Harmonization Guidelines 
for Good Clinical Practice (ICH harmonized tripartite 
guideline), the good epidemiological practice (Interna-
tional epidemiology association guidelines 2009), and 
the local laws and regulations in all participating coun-
tries. The protocol was approved by local hospitals Ethics 
Committees and the informed consent forms were sys-
tematically signed by all included patients.
Site and patient inclusion
A “master list” of private and public wards from each 
country was obtained and submitted for central rand-
omization by the study monitor. Each ward was to recruit 
around 10 to 15 consecutive patients, the recruitment 
being done by the principal physician in the ward.
The inclusion criteria were: Male or female patient 
≥18  years; abdominal or pelvic malignant tumor (colon, 
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rectum, stomach, liver, pancreas, prostate, uterus, ovaries, 
bladder and kidney); major surgical procedure for this malig-
nant tumor; informed consent signed prior to study entry.
The exclusion criteria were: An acute VTE event before 
the hospitalization within the last 6  months; long-term 
therapy with an anticoagulant agent for any reason (atrial 
fibrillation, previous VTE); life expectancy less than 
3 months; current participation in a clinical trial; follow-
up visit 6 weeks (at least 4 weeks) after surgery deemed 
to be impossible.
Data collection
Data was collected using paper case report form (CRF) 
at Visit 1 (at admission to hospital), Visit 2 (at discharge), 
and Visit 3 (6 weeks, at least 4 weeks after surgery as per 
usual practice). Accordingly, period A (in hospital) and 
period B (post discharge) are distinguished in this study 
(Fig.  1). The computerized handling of the data by the 
study monitor after receipt of the CRFs could have gen-
erated additional requests to which the Investigator was 
obliged to respond by confirming or modifying the data 
questioned.
Data management, review and validation
Source Data Verification (SDV) was performed on site, in 
10 % minimum of the active sites, chosen at random in 
each country. This SDV was performed by a good clini-
cal practice (GCP) qualified designated personnel in each 
country.
Endpoints
The primary endpoint was the rate of in-hospital (period 
A) VTE prophylaxis, according to ACCP 2008 guidelines.
The secondary endpoints were the rate of VTE prophy-
laxis according to ACCP guidelines after hospital dis-
charge (period B) and the reasons for lack of appropriate 
VTE prophylaxis during and after hospital discharge.
The information about these endpoints was collected 
in the questionnaires filled by the treating physician who 
was following his patient.
Data statistical analyses
The Analysis Set consisted of the patients with a malig-
nant tumor for whom major abdominal or pelvic surgery 
was documented, with complete information about age, 
sex and endpoints.
Generally, data was summarized and presented by type 
of surgery (abdominal, pelvic or abdominal  +  pelvic). 
Descriptive statistics were performed according to the 
type of criterion (quantitative or qualitative). Statistical 
tests were done (Chi square and Fisher exact test) with a 
type one error set at 0.05.
The influence of ward and patients’ characteristics on 
rates of period A, period B, and whole study VTE proph-
ylaxis according to ACCP 2008 guidelines was studied by 
a univariate analysis for 14 criteria. For more details, con-
sult the Additional file 1: appendix 1.
Criteria with a significance level of 0.15 or less were 
entered, consequently, in the multivariate analysis. A 
logistic regression model was implemented to explain the 
period A, the period B and the whole study adherences 
to ACCP 2008 guidelines. An ascending stepwise selec-
tion was used, with a significance level of 0.05. Egypt, the 
country with the highest number of patients included, 
was taken as reference.
Results
DIONYS was planned to be performed in 5–10 Latin 
American, African, and Middle Eastern countries. The 
following countries or cluster of countries (Egypt; Saudi 
Arabia; Kuwait and UAE [clustered data]; Lebanon; Syria; 
Mexico; Venezuela) were initially selected, but Syria 
was excluded later on because of the unstable security 
situation.
The analysis set contained a total of 921 patients, 
included in 80 wards, and divided into 3 surgical groups: 
[Abdominal], [Pelvic], and [Abdominal  +  Pelvic]. The 
recruitment of patients started in 2011 and the cutoff 
date was June 29, 2012 (Fig.  2). Twenty-eight patients 
discontinued the study (3 %) and those lost to follow-up 
were 6 (0.7 %).
Demographics and baseline characteristics
Table 1 shows the exact number of patients in the three 
groups with an equal distribution between abdominal 
and pelvic surgeries. The age average was approximately 
the same in the three surgical groups with predomi-
nance of the female gender in the [pelvic] and [abdomi-
nal + pelvic] groups, because of inclusion of gynecology 
wards.
The mean BMI (Calle et al. 1999) was for the 3 groups 
of surgeries in the overweight category (mean in the total 
group: 27.93 kg/m2).
About 40  % of the included patients had at least one 
risk factor for VTE on top of surgery and cancer. Diabe-
tes mellitus, moderate renal insufficiency, varicose veins 
and coronary artery diseases were on the top of the risk 
Fig. 1 Study design of DIONYS
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factors. A detailed description of these co-morbid condi-
tions is given in Additional file 2: appendix 2.
The majority of the patients were in a good general sta-
tus (KPS ≥ 80). All major abdominal organs, except liver, 
kidneys and prostate, were adequately represented in this 
study.
Surgery in a curative intent was done in the major-
ity of cases (82.6  %), since few patients (11.9  %) had 
an advanced cancer disease (stage IV, M+) for whom 
surgical treatment was palliative. Chemotherapy and/
or radiation therapy were used, either as neoadjuvant or 
during the study period, in 24.1 % of cases. These treat-
ments represent also a specific VTE risk factor associated 
to cancer. The detailed data of the patients’ cancer char-
acteristics are found in Additional file 3: appendix 3.
Rates of utilization of VTE prophylaxis: Period A, period B 
and throughout study period
To the majority of patients (90.3 %), at least one type of 
VTE prophylaxis was prescribed during the whole study 
period. A combination of mechanical and pharmaco-
logical prophylaxis was prescribed in 46.6 % while 40.7 % 
were given pharmacological treatment alone and 3 % only 
mechanical prophylaxis (Table 2).
The mechanical methods of prophylaxis included the 
graduated elastic compression (GEC) (38.4 %), the inter-
mittent pneumatic compression (IPC) (15  %) and band-
ages (9.3 %). The pharmacological methods of prophylaxis 
used mainly LMWH (86.6 %), while UFH was prescribed 
only in 3 % and OAC in 0.5 %. Among LMWH, enoxapa-
rin was the most frequently proposed (93.8 %).
Before surgery, VTE prophylaxis was exceptionally 
prescribed to the included patients (0.5  %). A great dif-
ference in rates of VTE prophylaxis was noted between 
periods A and B (90 versus 28.3  %). Whereas the two 
treatment modalities are frequently associated in the 
period A, in the latter, the mechanical methods are often 
neglected in favor of the pharmacological drugs.
Number of countries=8 
(N=991) 
Egypt=253, Saudi Arabia=99, 
Kuwait=65, UAE=35, Lebanon=154, 
Mexico=167, Venezuela=149
All Included Set 
N=922  







Lost to follow-up=6, 
Death=22 
Lost to follow-up: Abdominal=2, Pelvic=4;  
Death: Abdominal=14, Pelvic=2, 
Abdominal+Pelvic=6 
Excluded paent N=1 




Fig. 2 Overall participation status
Table 1 Patient demographics and characteristics by type of surgery
SD standard deviation, BMI body mass index, VTE venous thromboembolism, KPS Karnofsky performance status







Age (years) N 435 390 96 921
Mean (SD) 56.8 (14.1) 55.3 (14.3) 53.7 (12.9) 55.9 (14.1)
Median 57.0 56.5 53.5 57.0
Range 18–95 18–93 20–86 18–95
Gender N 435 390 96 921
 Male N (%) 214 (49.2) 78 (20.0) 27 (28.1) 319 (34.6)
 Female N (%) 221 (50.8) 312 (80.0) 69 (71.9) 602 (65.4)
BMI (kg/m2) N 415 379 93 887
N missing 20 11 3 34
Mean (SD) 27.03 (5.88) 28.81 (6.21) 28.35 (6.86) 27.93 (6.18)
Median 26.20 28.00 27.20 27.30
Range 10.4–67.0 15.3–66.7 14.3–59.6 10.4–67.0
≥One risk factor for VTE on top of surgery and 
cancer
N (%) 193 (44.4) 151 (38.7) 23 (24.0) 367 (39.8)
KPS score ≥80 N (%) 377 (86.6) 348 (89.3) 87 (90.7) 812 (88.2)
Laparotomy/open surgery N (%) 387 (89.0) 362 (92.8) 91 (94.8) 840 (91.2)
Use of mechanical VTE prophylaxis N (%) 182 (41.8) 195 (50.0) 36 (37.5) 413 (44.8)
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Omission of VTE prophylaxis in period A
Table  3 details the reasons for omission of prescription 
of VTE prophylaxis during hospitalization. The main rea-
son invoked by the physician was the low risk for VTE of 
the patient. Economic and logistic reasons were scarcely 
reported.
Omission of VTE prophylaxis in period B
The Additional file  4: appendix 4 indicates that the major 
reason for non-extension of VTE prophylaxis after hospi-
tal discharge was the clinical judgment of the physician that 
the patient did not need an extension of this prophylaxis 
(91.4 %). All other reasons were of no significant importance.
Adherence of prescribed prophylaxis to guidelines
In this study, the overall adherence to ACCP 2008 guide-
lines (concerning the type of prophylaxis, the drug dos-
age and the duration of treatment) was very low (12.3 %) 
and this was mainly due to a non-respect of these guide-
lines in period B. A high adherence rate (73.9  %) was 
noted during period A (Fig. 3).
Following univariate results, country, type of hos-
pital, total number of interventions per year and VTE 
prophylaxis protocol/policy were criteria found to be sig-
nificantly influencing the period A adherence rate. The 
period B adherence rate was also influenced, in addition 
to these criteria, by the type of surgery, the type of anes-
thesia, the disease status and the use of mechanical VTE 
prophylaxis. In the whole study rates, the same criteria 
were retained in addition to the presence of at least one 
medical history of VTE and hemorrhagic risk factor, the 
disease status and the current treatment.
The country, the type of hospital and the number of 
interventions per year were kept in the final multivariate 
logistic regression for the whole study and period A. In 
period B, the multivariate analysis retained the type of 
anesthesia and the use of mechanical VTE prophylaxis, in 
addition to the country. Lebanon was the most adherent 
country to VTE prophylaxis in accordance with ACCP 
guidelines 2008 (74.1  %), followed by Mexico (8.6  %), 
Egypt (8  %), the Cluster countries (4  %), Saudi Arabia 
(3.4 %) and Venezuela (1.7 %).
Reasons for patients’ non‑ compliance to prescription
Of 918 patients who were supposed to receive VTE 
prophylaxis as per the ACCP 2008 guidelines, 253 
patients (27.6  %) only took the correct treatment. The 
great majority did not receive this treatment because it 
was not prescribed by the physician. The non-compliance 
to a correct prophylaxis according to ACCP guidelines 
was a rare event (1.1  %). Table  4 shows the reasons for 
not complying with the prescribed treatment.
Complications during the study
When considering the whole study period, 202 patients 
(22.3  %) presented at least one complication. The most 
frequent events were wound infection, re-intervention/
revision and septicemia. It should be noted that bleeding 
Table 2 Number of patients for whom a VTE prophylaxis was prescribed by period of time
VTE venous thromboembolism
n (%) Abdominal (N = 435) Pelvic (N = 390) Abdominal + Pelvic (N = 96) Total (N = 921)
Period of intake
 Before surgery 1 (0.2) 4 (1.0) 0 5 (0.5)
 From surgery to hospital discharge 387 (89.0) 357 (91.5) 85 (88.5) 829 (90.0)
  None 48 (11.0) 33 (8.5) 11 (11.5) 92 (10.0)
  Mechanical only 10 (2.3) 18 (4.6) 0 28 (3.0)
  Pharmacological only 173 (39.8) 149 (38.2) 50 (52.1) 372 (40.4)
  Mechanical + Pharmacological 204 (46.9) 190 (48.7) 35 (36.5) 429 (46.6)
 After hospital discharge 104 (23.9) 126 (32.3) 31 (32.3) 261 (28.3)
  None 331 (76.1) 329 (67.7) 660 (71,7)
  Mechanical only 8 (1.8) 44 (9.1) 52 (5.6)
  Pharmacological only 90 (20.7) 105 (21.6) 195 (21.2)
  Mechanical + Pharmacological 6 (1.4) 8 (1.6) 14 (1.5)
 During the whole study (from surgery to post-
hospital discharge)
387 (89.0) 360 (92.3) 85 (88.5) 832 (90.3)
  None 48 (11.0) 30 (7.7) 11 (11.5) 89 (9.7)
  Mechanical only 10 (2.3) 18 (4.6) 0 28 (3.0)
  Pharmacological only 173 (39.8) 152 (39.0) 50 (52.1) 375 (40.7)
  Mechanical + Pharmacological 204 (46.9) 190 (48.7) 35 (36.5) 429 (46.6)
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causing hematoma on surgical site and VTE, two compli-
cations directly related to VTE prophylaxis, were particu-
larly rare events.
The possible association between the occurrence of 
complications and the adherence to ACCP 2008 guide-
lines during the whole study period was studied by a 
univariate analysis and showed no significant relation 
(Additional file 5: appendix 5).
Death occurred in 22 patients out of 921 (2.4 %). Pul-
monary embolism was diagnosed as cause of death in 5 
cases (0.54 %).
Treatment duration
Among LMWH, enoxaparin was the most frequently pre-
scribed for VTE prophylaxis (93.8 %). In 188 patients out 
of 921, enoxaparin was the only agent used for anti VTE 
prophylaxis (Additional file 6: appendix 6). The duration 
of treatment had a mean of 24.3 days.
Discussion
Because of the high risk of VTE in major surgical inter-
ventions, the ACCP proposed in 1986 a series of guide-
lines, recommending or suggesting an active strategy 
aiming to prevent these undesirable events (ACCP-
NHLBI 1986). These guidelines were systematically and 
periodically reviewed by ACCP, until the 8th edition in 
2008 (Hirsh et al. 2008) and the 9th edition in 2012 (Guy-
att et  al. 2012). DIONYS, realized in the time period of 
2010–2011, adopted the recommendations of 2008 and 
aimed to evaluate the hospitals and the physician’s adher-
ence to these guidelines as well as the compliance of 
patients with their prescriptions. The results of DIONYS 
registry are still applicable today because the 9th edition 
of the ACCP guidelines does not differ dramatically from 
the 8th edition, mainly regarding the abdominal and pel-
vic surgery for cancer (Guyatt et al. 2012).
Although the majority of patients received any type of 
VTE prophylaxis during the in-hospital period, only 79 % 
of them had prescriptions adherent to the ACCP 2008 
guidelines. The situation was totally different in the post-
discharge period when even less than 30 % received any 
prophylaxis, and only 19 % were adherent to guidelines. 
These results pinpoint the great lack of appropriate VTE 
prophylaxis in cancer surgical patients in the developing 
countries, mainly after discharge from hospital.
DIONYS has been the first study to evaluate the adher-
ence to the ACCP guidelines exclusively in cancer surgi-
cal patients. All other published data concerned medical 




Pelvic (N = 390) Abdominal + Pelvic 
(N = 96)
Total (N = 921)
No VTE prophylaxis prescribed during hospitalization 48 (11.0) 30 (7.7) 11 (11.5) 89 (9.7)
Reason
 Low risk of VTE 32 (66.7) 15 (50.0) 8 (72.7) 55 (61.8)
 No drug available at hospital 2 (4.2) 8 (26.7) 0 10 (11.2)
 Bleeding 6 (12.5) 3 (10.0) 0 9 (10.1)
 Economic reason 4 (8.3) 2 (6.7) 0 6 (6.7)
 Omission from principal investigator 0 2 (6.7) 3 (27.3) 5 (5.6)
 Nausea/vomiting 2 (4.2) 0 0 2 (2.2)
 Pulmonary embolism 1 (2.1) 0 0 1 (1.1)
 Other 1 (2.1) 0 0 1 (1.1)
73.9% of adherent prophylaxis 
at hospital 
18.9% of adherent prophylaxis 
after discharge























Fig. 3 Percentage of VTE prophylaxis adherent to ACCP 2008 guide-
lines at each period
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and/or surgical patients, including a variable number of 
cancer cases.
Many publications have reported different rates of 
adherence to the ACCP guidelines. In North America, 
a study by Yu (Yu et  al. 2007) on 123,304 hospitalized 
patients reported an overall 13.3 % in-hospital adherence 
rate with ACCP 1996 guidelines. Omission of prophy-
laxis was the primary reason for this low rate, followed 
by an inadequate duration of prophylaxis. Amin, in 2008, 
reported in the USA (Amin et al. 2008) that about 73 % 
of hospitalized cancer patients did not receive adequate 
VTE prophylaxis according to ACCP 2004 guidelines. 
This inappropriateness of treatment was equally distrib-
uted on medical and surgical patients, and was essentially 
due to unawareness of the physicians. These results were 
in agreement with other North American studies report-
ing similar weak adherence rates, both in medical (Gold-
haber and Tapson 2004; Kahn et  al. 2007) and surgical 
(Kakkar et al. 2003) wards.
Around the world, Bikdeli (Bikdeli and Sharif-Kashani 
2012), in a recent review, evaluated the VTE prophylaxis 
status of various patient subsets, and found important 
discrepancies between the different regions. Similarly, 
the ENDORSE study (Cohen et  al. 2008), which was a 
cross sectional survey assessing adherence to ACCP 
guidelines in 32 countries over 5 continents, revealed a 
rate of adherence to the guidelines in the risky surgical 
patients varying between 23 and 58  % in the countries 
included in the DIONYS study and between 0.2 and 
92 % worldwide, with the highest rates recorded in West-
ern Europe. The “prophylaxis appropriateness” assessed 
in the ENDORSE study included only the type of VTE 
prophylaxis prescribed for in-patients, irrelevant of the 
duration of prescription. Accordingly, it is likely that the 
overall adherence rate was overestimated in this study.
The subject was addressed by similar studies in the 
developing countries. The AVAIL ME study was a Mid-
dle Eastern comprehensive evaluation of VTE prophy-
laxis, conducted to assess the status of anticoagulation 
practices in seven countries (Taher et al. 2011). Of 2266 
patients, 82.9  % were eligible for prophylaxis according 
to the ACCP 2004 guidelines. Fifty-one percent obtained 
some form of VTE prophylaxis, but only 37.8 % accord-
ing to the ACCP guidelines. The study included medi-
cal and surgical patients and revealed that adherence to 
ACCP guidelines was 44 % in the surgical group, higher 
than that of the medical group. Later on, the AVAIL ME 
Extension study (Mokhtari et al. 2011) included ten Mid-
dle Eastern and Asian countries and defined the rate of 
patients receiving appropriate prophylaxis according to 
ACCP 2008 guidelines. Sixty-eight percent of patients 
were surgical, and cancer surgery constituted 14.1  % of 
these patients. Application of VTE prophylaxis guide-
lines was found only in 32 % of all patients. Thirty-nine 
percent of all surgical patients followed correctly the 
guidelines. The rate of patients who did not require or 
Table 4 Reasons for non compliance of patients to the prescribed treatment
Statistics Abdominal Pelvic Abdomi‑
nal + pelvic
All
Analysis set N 435 390 96 921
Missing data Nmiss 3 0 0 3
Prophylactic treatment should be prescribed N 432 390 96 918
 Prohylactic treatment prescribed and correctly taken n (%) 101 (23.4) 122 (31.3) 30 (31.3) 253 (27.6)
 Not taken n (%) 4 (0.9) 5 (1.3) 1 (1.0) 10 (1.1)
  If no, reason
  Economic reason n (%) 2 (0.5) 1 (0.3) 0 3 (0.3)
  Definitive prophylaxis discontinuation for medical reason n (%) 0 2 (0.5) 0 2 (0.2)
  No pharmacy/No drug available at pharmacy n (%) 0 1 (0.3) 0 1 (0.1)
  Discomfort n (%) 1 (0.2) 0 0 1 (0.1)
  Omission n (%) 0 1 (0.3) 0 1 (0.1)
  Other n (%) 0 0 1 (1.0) 1 (0.1)
  Discomfort + Definitive prophylaxis discontinuation for medical reason n (%) 1 (0.2) 0 0 1 (0.1)
  No or partial re-imbursement by Health system n (%) 0 0 0 0
  Self-injection not possible n (%) 0 0 0 0
  No-one to perform the injection n (%) 0 0 0 0
  Missing Nmiss 0 0 0 0
 Prophylactic treatment not prescribed and not taken n (%) 327 (75.7) 262 (67.2) 65 (67.7) 654 (71.2)
 Unknown n (%) 0 1 (0.3) 0 1 (0.1)
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had contraindications to VTE prophylaxis received it in 
78 and 66 % respectively. Similar to the ENDORSE study; 
AVAIL ME was cross-sectional using a 1-day assessment, 
so VTE prophylaxis duration appropriateness couldn’t be 
assessed.
In Lebanon, a multi-centric prospective chart review 
study of 840 patients (Zeitoun et al. 2009), showed appro-
priate VTE prophylaxis in about 65  % of patients at 
low risk, 30  % of patients at moderate risk and 61  % of 
patients at high risk with a total of 58.5 % of adherence 
to guidelines. Thirty-five (46.7 %) of the cancer patients 
received suitable prevention, whereas 40 (53.4  %) were 
improperly managed.
In a multi-centric Brazilian study regrouping four hos-
pitals (Deheinzelin et al. 2006), it was demonstrated that 
29 % of the highest surgical VTE risk patients were not 
prescribed prophylaxis correctly while 42  % of low-risk 
patients were over treated. In Africa, a survey among sur-
geons about their practice habits was conducted in Nige-
ria (Akinmoladun et  al. 2007) and Togo (Ouro-Bang’na 
Maman et  al. 2006) and showed that respectively 47.5 
and 6 % of them used prophylaxis routinely in major sur-
geries, according to their own evaluation of the risk.
However, all these publications did not tackle the 
adherence to guidelines in the post-discharge period, lim-
iting their figures mainly to the in-hospital period. Only 
recently, the DEIMOS registry (Arcelus and Felicissimo 
2013), a study similar in its methodology to the DIONYS 
registry and covering ten countries in Latin America, 
Africa and the Middle East, compared the real life VTE 
prophylaxis received by major orthopedic patients with 
the 2008 ACCP guidelines during the complete post-
surgery period: 85 % of patients were prescribed a VTE 
prophylaxis during hospitalization according to guide-
lines and 63.4 % after hospital discharge.
In DIONYS registry, the main reason for not prescrib-
ing VTE prophylaxis according to ACCP guidelines in 
the in-hospital period was a medical decision that the 
patients were at low risk of VTE (69 %), followed by the 
absence of treatment at the hospital, the occurrence of 
bleeding, some economic reasons and the omission of 
prescription by the surgeon. In the post-discharge period, 
the reason was simply a medical judgment that prophy-
laxis was not useful anymore (91 %). Several factors were 
studied by a logistic regression model looking for their 
eventual influence on the omission of appropriate VTE 
prophylaxis. The country, the type of hospital and the 
number of interventions per year and per hospital were 
retained for the in-hospital period. The country, the type 
of anesthesia and the use of mechanical VTE prophylaxis 
were the risk factors in the post-discharge period.
Although there was a widespread belief that VTE is 
low in cancer patients and that VTE treatment is less 
effective in cancer surgery (Amin et  al. 2008), Kakkar 
et  al. (Kakkar and Williamson 1999) reported that can-
cer patients undergoing surgery have twice the risk of 
postoperative VTE and more than three times the fatal 
risk of PE than patients who undergo surgery for benign 
condition.
Post-operative VTE, independently from other fac-
tors, has been found to be a poor prognostic factor in 
cancer patients even after complete surgical resection 
(Auer et al. 2012). In the ENOXACAN II and other stud-
ies (Bergqvist et al. 2002; Schmeler et al. 2013; Huo and 
Muntz 2009; Osborne et  al. 2008), LMWH prophylaxis 
for 4  weeks after surgery for abdominal or pelvic can-
cer was found safe and it significantly reduces the inci-
dence of venographically demonstrated thrombosis and 
the likelihood of symptomatic VTE (OR: 0.22), as com-
pared with LMWH prophylaxis for 1 week. In the Aris-
tos study (Agnelli et al. 2006), five risk factors, including 
advanced cancer, were identified as risk of VTE after sur-
gery. Lecumberri (Lecumberri et al. 2005) reported some 
oncologic trials showing that adjunction of LMWH to 
antineoplastic treatments had a beneficial effect on sur-
vival independently of all other cancer prognostic factors.
The barriers to appropriate VTE prophylaxis were 
comprehensively analyzed by Bikdeli (Bikdeli and Sharif-
Kashani 2012) who found many reasons for this inad-
equate care. Resulting from these barriers, VTE remains 
a major health problem in surgery: in three surgical ser-
vices in the USA, over the 10-year period since initial 
publication of the guidelines, VTE occurred in 0.46 % of 
surgical patients and the incidence increased gradually 
over the years despite 84 % of partial or complete adher-
ence to guidelines (Shackford et al. 2008).
Compliance with the VTE prophylaxis prescriptions, 
particularly in the post-discharge period, should be dis-
tinguished from the adherence to ACCP guidelines, 
since the latter depends on a physician decision while 
the former is patient-dependent. The non -compliance of 
patients with prescriptions, in the DIONYS registry, was 
only 1.1  % emphasizing once again that the problem of 
inappropriateness of VTE prophylaxis resides in the phy-
sician behavior. Bikdeli (Bikdeli and Sharif-Kashani 2012) 
analyzed also this condition and identified, as reasons for 
it, the injection site pain, bruises, systemic complications, 
skin breaks and local discomfort.
Prophylactic doses of anticoagulation have not been 
associated with hemorrhagic complications. In our 
study, only 0.7  % of the patients had a major bleeding. 
Our data are in line with the earlier studies that showed 
major bleeding occurring in 1.2  % in cancer surgery as 
well as in outpatient setting (Kahn et al. 2012; Rasmussen 
et al. 2006). In DIONYS, VTE related death occurred in 
0.54 % of the patients. Other studies showed that death 
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secondary to VTE was between 0 and 0.8 % (Agnelli et al. 
2006; Kahn et al. 2012; Rasmussen et al. 2006).
The method of VTE prophylaxis used in DIONYS 
was mainly pharmacological and the most prescribed 
agent during the whole study was enoxaparin (81.3  %). 
It is universally admitted that the VTE prophylaxis may 
be pharmaceutical, mechanical or combined. If there is 
contraindication to anticoagulation or recurrence of PE 
despite optimal anticoagulation, vena cava filters (VCF) 
may be considered (Farge et al. 2013).
Among pharmaceutical agents, LMWH are the pre-
ferred agents for the initial and long term VTE proph-
ylaxis in patients with neoplastic disease, based on 
randomized clinical trials. They are given once daily, 
do not usually require routine monitoring but should 
be given with precaution in renal insufficiency patients 
(Streiff 2009; Streiff 2011). In cancer patients, LMWHs 
compared to oral warfarin are at least as effective. Less 
osteoblast activation is observed in response to LMWH 
exposure (Deitcher 2003).
DIONYS has both strengths and limitations. It was 
a large observational, prospective and multinational 
registry, conducted on patients from seven developing 
countries across three continents. It left the physicians 
free to prescribe whatever VTE prophylaxis they found 
appropriate, thus studying real life application of proph-
ylaxis according to ACCP guidelines. Another strong 
point was that, even though some studies concerning 
the adherence to ACCP guidelines were conducted pre-
viously, DIONYS, to our knowledge, was the first multi-
national study, conceived in these countries and taking 
into consideration not only the type, but also the dura-
tion of VTE prophylaxis, and its extension to the post-
discharge period, in abdominal and pelvic surgery for 
cancer.
However, in DIONYS, there was a possibility of a selec-
tion bias in case the master-list of hospitals was not com-
plete in all countries. Another relative limitation was 
the fact that this registry studied the adherence of VTE 
prophylaxis to ACCP 2008 guidelines, and since that 
time, newer 2012 guidelines had emerged, showing the 
need for newer studies. DIONYS only assessed the appli-
cation of VTE prophylaxis guidelines in abdominal and 
pelvic cancer surgery, thus the results may not be appli-
cable to patients undergoing other cancer surgeries.
In conclusion, DIONYS revealed that a large gap 
remains, at least in the developing countries, between 
real life practices of VTE prophylaxis in cancer sur-
gery and the international ACCP guidelines. The 
non-adherence to guidelines could be improved by 
arranging continuous education programs for the 
medical team, increasing their awareness to the prob-
lem. Prophylaxis protocols should be established and 
implemented at both the hospital and the national lev-
els trying to promote the recommended policies in the 
real life practice.
DIONYS investigators
Registry Scientific Committee: Négib Elias Geahchan. 
The list of investigators who recruited patients in the 
DIONYS registry is available as Additional file 1: Appen-
dix 1.
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